Mineral supplement
Zinc Picolinate
Zinc picolinate is zinc complexed with picolinic acid; the app lists a half-life of 6 hours, a figure none of the retrieved sources gives.1
Zinc Picolinate after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.
Drawn from the half-life in the app's model, ~6 h. The model's figures
- Compound
- Zinc Picolinate
- Symbol
- ZN
- Family
- Supplements
- Parts
- 13
- References
- 6
- Checked
- Last reviewed . Sources are listed below.
Overview
Zinc picolinate is one of several complexed forms of zinc, with picolinic acid as the complexing partner, and the app files it under minerals within supplements.1 Schoofs and colleagues, in a 2024 review in Molecules, describe zinc as "an essential trace element required for various physiological processes".2 The same review summarises that zinc "participates in over 300 enzymatic reactions, metabolic functions, regulation of gene expression, apoptosis and immune modulation"; this describes zinc in general and not the picolinate form.2
The human studies retrieved for zinc picolinate are a four-week crossover absorption trial in 15 healthy volunteers, two taste-disorder studies from one Japanese department and an 8-week supplementation study in patients with chronic obstructive pulmonary disease (COPD).1,3,4,5 The app grades the evidence for zinc picolinate as strong. Nothing in the PubMed records of these four studies states a sponsor, apart from the publication type "Research Support, Non-U.S. Gov't" on two of them.1,3
How it works
Sources in this part
No human mechanistic study of the picolinate form was identified among the first 20 titles read for each of two PubMed searches (1339 and 28 records matched); the full result lists were not read. Barrie and colleagues write that their results "suggest that zinc absorption in humans can be improved by complexing zinc with picolinic acid".1 The Schoofs review notes that "The absorption of zinc can be influenced by the presence of other trace elements, such as copper and iron".2 It states that "Phytate binds to zinc, forming complexes that cannot be absorbed by the body", and that for oral and dermal intake "the composition of the zinc salt has a significant influence on the absorption of zinc".2 The review also says "Zinc-induced copper deficiency is a consequence of an excessive dietary intake of zinc, which leads to a reduced absorption of copper in the body, even at low doses above the recommendation of the RDA".2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~6 h
- Bioavailability
- 60%
- Typical dose
- 15–30 mg/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the retrieved sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~6 h | No half-life for zinc picolinate in the records retrieved |
| Bioavailability | 60% | No bioavailability percentage for zinc picolinate in the records retrieved; Barrie and colleagues measured zinc in hair, urine, erythrocytes and serum rather than reporting a percentage1 |
| Time to peak | ~2 h | No time to peak for zinc picolinate in the records retrieved |
| Duration of activity | ~12 h | No duration of activity for zinc picolinate in the records retrieved |
| Model | One compartment | No pharmacokinetic model for zinc picolinate in the records retrieved |
| Route | Oral | Oral administration in the Barrie trial1 |
| Absorption of dietary zinc in adults | Not an app figure | A review reports that modelling of zinc absorption found "the maximal absorption of zinc in adults is approximately 6 mg/day"; the figure is for dietary zinc in general and not for the picolinate form2 |
Because no retrieved source gives a half-life, bioavailability or time to peak for zinc picolinate, none of the app's figures here is confirmed or contradicted by a source, and no level chart is drawn.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Barrie and colleagues, Agents and Actions 19871 | Double-blind, randomized four-period crossover trial with placebo and three zinc forms1 | 15 healthy volunteers1 | Zinc picolinate, zinc citrate or zinc gluconate, each equivalent to 50 mg elemental zinc per day, or placebo; four-week periods1 | Hair, urine and erythrocyte zinc rose significantly with zinc picolinate (p less than 0.005, p less than 0.001, p less than 0.001); no significant change with zinc gluconate, zinc citrate or placebo; small, insignificant rise in serum zinc with picolinate, citrate and placebo1 |
| Sakai and colleagues, Nihon Jibiinkoka Gakkai Kaiho 19953 | Double-blind study of zinc picolinate against placebo3 | Patients with zinc-deficient and idiopathic taste disorders3 | Dose and length not given in the PubMed record | Significant differences from placebo in filter-paper disk improvement and in serum zinc; no significant difference in total subjective recovery or in the whole-mouth method3 |
| Sakai and colleagues, Acta Oto-Laryngologica Supplementum 20024 | Double-blind, placebo-controlled trial4 | 73 patients with an idiopathic zinc-deficiency taste disorder completed the trial; 37 in the zinc group4 | 29 mg of zinc picolinate orally by capsule 3 times a day for 3 months, against placebo4 | No significant difference in subjective symptoms or whole-mouth taste sensation; filter paper disk improvement and serum zinc significantly better with zinc4 |
| Kirkil and colleagues, Respiratory Medicine 20085 | Study listed in PubMed as a randomized controlled trial; supplementation with baseline comparison to healthy controls5 | 30 patients with COPD and 15 healthy non-smokers matched for age and sex5 | 22 mg of zinc picolinate daily for 8 weeks5 | Significant increases in mean SOD and zinc levels; no significant change in MDA, CAT, FEV1 (% predicted) or FEV1/FVC (%)5 |
Sources in this part
Deeper analysis: Barrie and colleagues, absorption crossover trial (1987)
Barrie and colleagues reported the trial in Agents and Actions in 1987; the PubMed record lists the publication types "Randomized Controlled Trial" and "Comparative Study".1 The record describes 15 healthy volunteers randomly divided into four groups, each rotating "for four week periods through a random sequence of oral supplementation including: zinc picolinate, zinc citrate, and zinc gluconate (equivalent to 50 mg elemental zinc per day) and placebo".1 Zinc was measured in hair, urine, erythrocytes and serum before and after each period.1 At the end of four weeks, hair, urine and erythrocyte zinc "rose significantly (p less than 0.005, p less than 0.001, and p less than 0.001) during zinc picolinate administration", with "no significant change in any of these parameters from zinc gluconate, zinc citrate or placebo administration".1 Serum zinc, the null result in this trial, showed "a small, insignificant rise" during zinc picolinate, zinc citrate and placebo supplementation.1 The authors write that the results "suggest" absorption "can be improved by complexing zinc with picolinic acid".1 The record states no limitations, no adverse events or dropouts, no sponsor beyond the publication type "Research Support, Non-U.S. Gov't", and no author ties; it lists no affiliations.1
Deeper analysis: Sakai and colleagues, taste-disorder trials (1995 and 2002)
Sakai and colleagues reported a double-blind study in Nihon Jibiinkoka Gakkai Kaiho in 1995 and a double-blind, placebo-controlled trial in Acta Oto-Laryngologica Supplementum in 2002, both from the Department of Otolaryngology (Otorhinolaryngology in the 1995 record), Nihon University School of Medicine, Tokyo.3,4 The 2002 trial enrolled patients with "an idiopathic zinc-deficiency taste disorder"; 73 completed it, and 37 of them were in the zinc group.4 The zinc group received "29 mg of zinc picolinate orally by capsule 3 times a day for 3 months"; the record does not say whether 29 mg refers to elemental zinc.4 The record states that "No significant difference was noted between the treatment and placebo groups in terms of improvement in subjective symptoms or whole-mouth taste sensation".4 It adds that taste assessed with the filter paper disk method "showed significantly better improvement for the group given zinc", and that the serum zinc level was significantly higher in that group than in the placebo group.4 The 1995 record reports the same pattern: a significant difference from placebo on the filter-paper disk method and serum zinc, and no significant difference in "total subjective recovery" or the whole-mouth method.3 The 1995 authors conclude that "the administration of zinc picolinate is effective for patients with zinc-deficient and idiopathic taste disorders".3 The records do not label a primary outcome, state limitations, report adverse events or dropouts, or say whether the two reports describe overlapping patients; the 1995 record carries the publication type "Research Support, Non-U.S. Gov't" and the 2002 record names no sponsor or author ties.3,4
Deeper analysis: Kirkil and colleagues, COPD supplementation study (2008)
Kirkil and colleagues, of the Department of Chest Disease, Faculty of Medicine, Firat University, Elazig, Turkey, reported the study in Respiratory Medicine in 2008.5 They measured baseline spirometry, plasma malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT) and zinc in 30 patients with stable COPD and 15 age- and sex-matched healthy non-smokers; the record states that "All parameters were repeated after 8 weeks of supplementation with 22 mg of zinc picolinate daily" without saying which group was supplemented.5 At baseline, MDA was higher in the COPD group (0.51+/-0.15 vs 0.39+/-0.15 nmol/mL, p=0.037), while SOD, CAT and zinc levels were lower than in controls.5 After supplementation, "no significant change in mean MDA, CAT levels and forced expiratory volume in one second (FEV1) (% predicted), and FEV1/FVC (%) parameters was observed", while SOD and zinc levels rose significantly.5 The correlations between MDA, SOD, CAT, zinc and spirometric measurements "were not significant on either day 1 nor 8 weeks of zinc supplementation".5 The authors write that supplementation "may have favorable effects on oxidant-antioxidant balance in patients with COPD", that "The lack of an effect on PFT may be due to the short duration of the supplementation", and that "Longer duration of zinc supplementation may be necessary to see clinical benefit".5 The PubMed record lists the study as a randomized controlled trial but does not describe a placebo group or say whether the healthy controls were supplemented, and it gives no funding statement, author ties, adverse events or dropouts.5
Doses reported in studies and on labels
| Source | Dose | Length and comparator | People |
|---|---|---|---|
| Barrie and colleagues 1987, oral1 | Zinc picolinate, citrate or gluconate, each equivalent to 50 mg elemental zinc per day1 | Four-week periods in a crossover, with placebo1 | 15 healthy volunteers1 |
| Sakai and colleagues 2002, oral capsule4 | 29 mg of zinc picolinate 3 times a day4 | 3 months, against placebo4 | 37 in the zinc group among 73 completers with idiopathic zinc-deficiency taste disorder4 |
| Kirkil and colleagues 20085 | 22 mg of zinc picolinate daily5 | 8 weeks, with before-and-after measures5 | 30 patients with COPD and 15 healthy non-smokers5 |
| Schoofs and colleagues 2024 review, WHO dietary reference value | 6.7 to 15 mg per day, as the review reports the WHO value2 | Reference value for zinc intake, not a trial | Population not specified in the quoted passage2 |
| Schoofs and colleagues 2024 review, EFSA and FDA | EFSA tolerable upper intake level (UL) of 25 mg per day for an adult; FDA figure of 40 mg per day2 | Upper limits for chronic daily intake, not a trial | Adults (EFSA figure); the review does not restate an age group for the FDA figure2 |
| The app's typical dose | 15–30 mg/day, oral | Not a trial or label figure | Not applicable |
Sources in this part
A DailyMed search for "zinc picolinate" returned four labels, all multi-ingredient products, and none was read for dose statements, so no single-ingredient zinc picolinate label is cited.
Side effects reported
Sources in this part
The four zinc picolinate studies' PubMed records give no adverse event, discontinuation or death figures. The Schoofs review, which covers zinc in general and not the picolinate form, states that "Symptoms of acute zinc toxicity include headache, nausea, vomiting, diarrhea, abdominal discomfort" and, in rare cases, metabolic imbalances and severe neurological symptoms.2 It cites a study of 47 healthy volunteers in which "84% of women and 18% of men reported symptoms such as nausea, loss of appetite and abdominal cramps after the intake of 220 mg zinc sulfate containing 50 mg elemental zinc for six weeks, three times per day".2 The review's summary states that "An excess of the recommended daily intake may result in symptoms such as anemia, neutropenia and zinc-induced copper deficiency".2 It also states that "the concurrent use of oral zinc in combination with quinolone antibiotics (topoisomerase inhibitors) or tetracycline antibiotics (protein synthesis inhibitors) can interfere with the effectiveness in combating bacterial infections".2 The review reports no external funding and declares no conflicts of interest.2
Bloodwork and markers
Sources in this part
The app lists no health markers to monitor for zinc picolinate. Barrie and colleagues measured zinc in hair, urine, erythrocytes and serum, and Sakai and colleagues (2002) report serum zinc, which was significantly higher in the zinc group than in the placebo group.1,4 Kirkil and colleagues measured plasma MDA, SOD, CAT and zinc together with spirometry (FEV1 and FEV1/FVC).5 The Schoofs review says that when zinc toxicity is suspected from oral intake, "it can be diagnosed through elevated zinc levels in the blood or reduced copper and ceruloplasmin levels".2
Regulatory and anti-doping status
Sources in this part
The Schoofs review gives tolerable upper intake levels for zinc of 25 mg per day (EFSA) and 40 mg per day (FDA), and notes that "Beyond this threshold, there is a risk of impairing copper homeostasis".2 The review's conclusion states that after reviewing the studies, "the EFSA's upper intake level of 25 mg per day is more reasonable for avoiding potential negative effects of zinc toxicity".2 The text of the WADA 2026 Prohibited List, as retrieved from WADA's PDF (38,830 characters), contains no mention of zinc.6 No single-ingredient zinc picolinate drug label or regulator assessment was retrieved; the DailyMed search returned only multi-ingredient products.
What is not known
Sources in this part
No half-life, bioavailability percentage, time to peak or pharmacokinetic model for zinc picolinate was identified in PubMed, so the app's figures for these stand here without a reported figure beside them. The retrieved studies of zinc picolinate in people enrolled 15 healthy volunteers (Barrie), 73 completers (Sakai 2002, the 1995 record gives no number) and 30 patients with COPD plus 15 healthy non-smokers (Kirkil), and for each the full text was not retrieved, so design details beyond the PubMed record are not covered here.1,4,5 The only comparison of zinc forms retrieved is the Barrie trial, which tested zinc picolinate, zinc citrate and zinc gluconate at one dose level in 15 volunteers.1 The titles of the first 20 of 55 ClinicalTrials.gov records returned for "zinc picolinate" did not name a zinc picolinate trial; the other 35 records and the intervention fields were not read.
Frequently asked questions
What is the half-life of zinc picolinate?
The app lists a half-life of about 6 hours for zinc picolinate. None of the sources retrieved gives a half-life figure for zinc picolinate.
What is zinc picolinate?
Is zinc picolinate banned by WADA?
The text of the WADA 2026 Prohibited List retrieved for this work contains no mention of zinc.6
Is zinc picolinate absorbed better than zinc citrate or zinc gluconate?
In one 1987 crossover trial of 15 healthy volunteers, hair, urine and erythrocyte zinc rose significantly with zinc picolinate, with no significant change from zinc gluconate, zinc citrate or placebo.1 Serum zinc showed a small, insignificant rise with picolinate, citrate and placebo, and the retrieved records include no second trial of the comparison.1
Has zinc picolinate been studied for taste disorders?
Sakai and colleagues reported a double-blind, placebo-controlled trial in 2002 in 73 patients with an idiopathic zinc-deficiency taste disorder who completed it.4 The record reports no significant difference in subjective symptoms or whole-mouth taste sensation, and significantly better filter paper disk improvement and serum zinc with zinc.4
Has zinc picolinate been studied in COPD?
Kirkil and colleagues reported an 8-week supplementation study with 22 mg of zinc picolinate daily in 30 patients with stable COPD, with 15 healthy non-smokers as a comparison group at baseline.5 SOD and zinc levels rose significantly, and no significant change was observed in MDA, CAT, FEV1 (% predicted) or FEV1/FVC (%).5
Does zinc affect copper?
What side effects are reported with zinc?
A 2024 review lists headache, nausea, vomiting, diarrhea and abdominal discomfort as symptoms of acute zinc toxicity.2 The PubMed records of the four zinc picolinate studies give no adverse event figures.
Guides, tools and comparisons
References
- Barrie SA, et al. Comparative absorption of zinc picolinate, zinc citrate and zinc gluconate in humans. Agents Actions 1987;21(1-2):223-8. PMID 3630857
- Schoofs H, et al. Zinc Toxicity: Understanding the Limits. Molecules 2024;29(13). PMC11243279
- Sakai F, et al. Therapeutic efficacy of zinc picolinate in patients with taste disorders. Nihon Jibiinkoka Gakkai Kaiho 1995;98(7):1135-9. PMID 7562235
- Sakai F, et al. Double-blind, placebo-controlled trial of zinc picolinate for taste disorders. Acta Otolaryngol Suppl 2002;(546):129-33. PMID 12132610
- Kirkil G, et al. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease. Respir Med 2008;102(6):840-4. PMID 18295467
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list